NuCana Stock Forecast, Price & News

-0.04 (-1.66 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume126,954 shs
Average Volume502,288 shs
Market Capitalization$123.62 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NCNA News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

NuCana logo

About NuCana

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology consists of acelarin, NUC-3373 and NUC-7738. The company was founded by Hugh Stephen Griffith and Christopher Barry Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.90 out of 5 stars

Medical Sector

658th out of 1,352 stocks

Pharmaceutical Preparations Industry

314th out of 665 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NuCana (NASDAQ:NCNA) Frequently Asked Questions

Is NuCana a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NuCana stock.
View analyst ratings for NuCana
or view top-rated stocks.

What stocks does MarketBeat like better than NuCana?

Wall Street analysts have given NuCana a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NuCana wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NuCana?

NuCana saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 1,020,000 shares, an increase of 21.6% from the August 15th total of 838,700 shares. Based on an average trading volume of 528,800 shares, the short-interest ratio is presently 1.9 days. Currently, 2.4% of the company's stock are sold short.
View NuCana's Short Interest

When is NuCana's next earnings date?

NuCana is scheduled to release its next quarterly earnings announcement on Thursday, November 18th 2021.
View our earnings forecast for NuCana

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) released its quarterly earnings data on Wednesday, August, 18th. The company reported ($17.00) earnings per share for the quarter, beating the Zacks' consensus estimate of ($19.27) by $2.27.
View NuCana's earnings history

How has NuCana's stock price been impacted by Coronavirus (COVID-19)?

NuCana's stock was trading at $6.34 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NCNA shares have decreased by 62.6% and is now trading at $2.37.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NCNA?

4 brokerages have issued 12 month price objectives for NuCana's shares. Their forecasts range from $10.00 to $22.00. On average, they expect NuCana's stock price to reach $17.67 in the next twelve months. This suggests a possible upside of 645.4% from the stock's current price.
View analysts' price targets for NuCana
or view top-rated stocks among Wall Street analysts.

Who are NuCana's key executives?

NuCana's management team includes the following people:
  • Hugh Stephen Griffith, Chief Executive Officer & Executive Director
  • Donald Munoz, Chief Financial Officer
  • Elisabeth Oelmann, Senior VP-Medical & Clinical Development
  • Jeffrey D. Bloss, Chief Medical Officer
  • Theresa Margaret Bruce, Senior Vice President-Clinical Operations

Who are some of NuCana's key competitors?

What other stocks do shareholders of NuCana own?

When did NuCana IPO?

(NCNA) raised $100 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

What is NuCana's stock symbol?

NuCana trades on the NASDAQ under the ticker symbol "NCNA."

Who are NuCana's major shareholders?

NuCana's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.02%), FMR LLC (1.29%), Morgan Stanley (0.92%), Morgan Stanley (0.87%), Harvard Management Co. Inc. (0.80%) and Monashee Investment Management LLC (0.41%).

Which institutional investors are selling NuCana stock?

NCNA stock was sold by a variety of institutional investors in the last quarter, including Harvard Management Co. Inc., Susquehanna Fundamental Investments LLC, and Millennium Management LLC.

Which institutional investors are buying NuCana stock?

NCNA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Morgan Stanley, FMR LLC, Monashee Investment Management LLC, Laurion Capital Management LP, Goldman Sachs Group Inc., and Commonwealth of Pennsylvania Public School Empls Retrmt SYS.

How do I buy shares of NuCana?

Shares of NCNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuCana's stock price today?

One share of NCNA stock can currently be purchased for approximately $2.37.

How much money does NuCana make?

NuCana has a market capitalization of $123.62 million. The company earns $-39,400,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does NuCana have?

NuCana employs 27 workers across the globe.

What is NuCana's official website?

The official website for NuCana is

Where are NuCana's headquarters?

NuCana is headquartered at 3 Lochside Way, Edinburgh X0, EH12 9DT.

How can I contact NuCana?

NuCana's mailing address is 3 Lochside Way, Edinburgh X0, EH12 9DT. The company can be reached via phone at 441313571111 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.